Home › Research › Treatments
The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study
Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R et al.. Archives of internal medicine, 2002-10-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Background After the double-blind, placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial ended in February 1997, randomized patients were offered active study medication for a further period of observation. Objective To refine the estimates of the long-term effects of antihypertensive therapy on the incidence of dementia. Methods Eligible patients had no dementia and were at least 60 years old. Their systolic blood pressure at entry was 160 to 219 mm Hg, with diastolic blood pressure below 95 mm Hg. Antihypertensive therapy was started immediately after randomization in the active treatment group, but only after termination of the double-blind trial in the control patients. Treatment consisted of nitrendipine (10-40 mg/d), with the possible addition of enalapril maleate (5-20 mg/d), hydrochlorothiazide (12.5-25 mg/d), or both add-on drugs. Results Median follow-up increased from 2.0 years in the double-blind trial to 3.9 years overall. The incidence of dementia doubled from 32 to 64 cases, 41 of whom had Alzheimer disease. Throughout follow-up, systolic/diastolic blood pressure was 7.0/3.2 mm Hg higher in the 1417 control patients than in the 1485 subjects randomized to active treatment. At the last examination, the blood pressure difference was still 4.2/2.9 mm Hg; 48.1%, 26.4%, and 11.4% of the control patients were taking nitrendipine, enalapril, and/or hydrochlorothiazide, whereas in the active treatment group these proportions were 70.2%, 35.4%, and 18.4%, respectively. Compared with the controls, long-term antihypertensive therapy reduced the risk of dementia by 55%, from 7.4 to 3.3 cases per 1000 patient-years (43 vs 21 cases, P Conclusion The extended follow-up of Syst-Eur patients reinforces the evidence that blood pressure-lowering therapy initiated with a long-acting dihydropyridine protects against dementia in older patients with systolic hypertension.
What this study adds
Evidence grade: High
This is a trial of 1,485 participants. In the extended follow-up of the Syst-Eur study, long-term antihypertensive therapy reduced the risk of dementia by 55% compared with controls. Reported effect size: 48.1%; 26.4%; 11.4%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Forette, F., Seux, M. L., Staessen, J. A., Thijs, L., Babarskiene, M. R., Babeanu, S., et al. (2002). The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Archives of internal medicine. https://doi.org/10.1001/archinte.162.18.2046
Vancouver
Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Archives of internal medicine. 2002. doi:10.1001/archinte.162.18.2046. PMID: 12374512.
BibTeX
@article{forette2002-12374512,
author = {Forette, F. and Seux, M. L. and Staessen, J. A. and Thijs, L. and Babarskiene, M. R. and Babeanu, S. and Bossini, A. and Fagard, R. and others},
title = {{The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study}},
journal = {Archives of internal medicine},
year = {2002},
doi = {10.1001/archinte.162.18.2046},
pmid = {12374512},
url = {https://doi.org/10.1001/archinte.162.18.2046}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Median follow-up increased from 2.0 years in the double-blind trial to 3.9 years overall.
- Compared with the controls, long-term antihypertensive therapy reduced the risk of dementia by 55%, from 7.4 to 3.3 cases per 1000 patient-years (43 vs 21 cases, P<.001).
Why it matters
In the extended follow-up of the Syst-Eur study, long-term antihypertensive therapy reduced the risk of dementia by 55% compared with controls. This reinforces evidence that blood pressure-lowering therapy started with a long-acting dihydropyridine may reduce dementia risk in older patients with systolic hypertension.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants1,485
- Effect size48.1%; 26.4%; 11.4%
- Evidence strengthHigh
How this study scored 75/100
Published in a peer-reviewed journal, and it is a randomized controlled trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Archives of internal medicine) |
| Journal's citation record | 3 / 4 | Archives of Internal Medicine: journal h-index 462 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2002 — older than 20 years, still counted |
| Sample size | 3 / 4 | 1,485 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 6 / 7 | Cited 896 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 34.5 citations a year over 26 year(s) since 2002 |
| Impact for its field and year | 5 / 6 | Cited 26.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 50 other studies in this library |
| Still being cited | 2 / 4 | Cited 39 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Françoise Forette: h-index 47 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Université Paris Cité: institution h-index 841 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12374512) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 75 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/archinte.162.18.2046
- PubMed: 12374512
- Original source →
- Free full text: lirias.kuleuven.be →
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
50 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.